Case report: Giant lymph node metastases: a new opportunity for cancer radioimmunotherapy?
Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considere...
Saved in:
Published in | Frontiers in immunology Vol. 15; p. 1357601 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.
In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.
The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy. |
---|---|
AbstractList | BackgroundDespite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.Case presentationIn this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.ConclusionsThe combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy. Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.BackgroundDespite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness.In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.Case presentationIn this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months.The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.ConclusionsThe combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy. Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness. In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months. The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy. |
Author | Li, Dan Bian, Yuan Zhang, Zhenhua Deng, Xiangyu Wen, Qinglian |
AuthorAffiliation | 2 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan , China 1 Department of Oncology, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan , China |
AuthorAffiliation_xml | – name: 1 Department of Oncology, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan , China – name: 2 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan , China |
Author_xml | – sequence: 1 givenname: Yuan surname: Bian fullname: Bian, Yuan – sequence: 2 givenname: Zhenhua surname: Zhang fullname: Zhang, Zhenhua – sequence: 3 givenname: Xiangyu surname: Deng fullname: Deng, Xiangyu – sequence: 4 givenname: Qinglian surname: Wen fullname: Wen, Qinglian – sequence: 5 givenname: Dan surname: Li fullname: Li, Dan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38348039$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkk9v1DAQxS1URMvSL8AB-chlF_9LnPRSoRWUSpW4wIWLNbHH3VSJHewEtN8eb3epWsvSjOyf3rPG7y05CzEgIe8520jZtJ98P47LRjChNlxWumb8Fbngda3WUgh19qw_J5c5P7CyVCulrN6Qc9lI1TDZXpBfW8hIE04xzVf0pocw02E_TjsaokM64gy5bMxXFGjAvzROB3QJ_bynPiZqIVhMNIHr4-FJIc47TDDtr9-R1x6GjJenuiI_v375sf22vvt-c7v9fLe2SrB5rXWHsmuVrhVjnXLSIkrNRd35BhzwGphSbWdrjt568BwKwkoVrvJOd3JFbo-6LsKDmVI_QtqbCL15PIjp3kCaezug4a7ToMpMGu9VVVwb1YrK2sZJ3fIykRW5PmpNSzeisxjmBMML0Zc3od-Z-_jHcNZUbSV0Ufh4Ukjx94J5NmOfLQ4DBIxLNqIVNdO61rygH56bPbn8_50CiCNgU8w5oX9CODOHFJjHFJhDCswpBfIf_uCnrQ |
Cites_doi | 10.1001/jama.2017.11470 10.6004/jnccn.2015.0055 10.1111/his.13723 10.4161/onci.28518 10.1136/jitc-2020-002038 10.1056/NEJMoa1309748 10.1038/modpathol.2015.108 10.1016/j.radonc.2018.03.003 10.1016/j.cell.2023.02.021 10.1016/j.ygyno.2012.12.035 10.1097/PAS.0000000000001506 10.1016/S0140-6736(17)31607-0 10.1016/j.ijrobp.2012.01.070 10.1016/j.cell.2018.09.035 10.1136/ijgc-2023-004705 10.1146/annurev-immunol-042718-041717 10.1186/s13045-017-0541-9 10.1200/JCO.18.01265 10.1016/j.cell.2016.12.022 10.1158/2326-6066.CIR-14-0196 10.1038/modpathol.2016.221 10.1038/s41379-019-0433-3 10.3322/caac.21660 10.1200/JCO.2017.74.5471 10.1158/1078-0432.CCR-14-2824 10.1056/NEJMoa1613210 10.1016/S1470-2045(15)70004-5 10.1158/1078-0432.CCR-20-0776 10.1200/JCO.2022.40.16_suppl.5528 10.1001/jamaoncol.2019.3857 10.1126/sciimmunol.abg3551 10.3802/jgo.2016.27.e43 10.1186/s13045-021-01045-x 10.1016/j.cell.2022.04.019 10.1038/s41467-023-39383-8 10.1002/ijgo.13865 10.1016/j.semcdb.2014.10.002 10.1016/S1470-2045(23)00411-4 10.1016/j.cell.2008.07.001 10.1200/JCO.19.00739 |
ContentType | Journal Article |
Copyright | Copyright © 2024 Bian, Zhang, Deng, Wen and Li. Copyright © 2024 Bian, Zhang, Deng, Wen and Li 2024 Bian, Zhang, Deng, Wen and Li |
Copyright_xml | – notice: Copyright © 2024 Bian, Zhang, Deng, Wen and Li. – notice: Copyright © 2024 Bian, Zhang, Deng, Wen and Li 2024 Bian, Zhang, Deng, Wen and Li |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2024.1357601 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_1db7a42248ff453b984925cc8d379180 PMC10859527 38348039 10_3389_fimmu_2024_1357601 |
Genre | Case Reports |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c420t-77be3b9476400b4d3cee37126bf8ada16a0449bc61efcfaf1ad3c0af12d5fd7b3 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:29:42 EDT 2025 Thu Aug 21 18:35:16 EDT 2025 Fri Jul 11 09:40:27 EDT 2025 Mon Jul 21 05:58:01 EDT 2025 Tue Jul 01 03:33:47 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | radiotherapy case report cervical cancer immunotherapy lymph node metastasis |
Language | English |
License | Copyright © 2024 Bian, Zhang, Deng, Wen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c420t-77be3b9476400b4d3cee37126bf8ada16a0449bc61efcfaf1ad3c0af12d5fd7b3 |
Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 Christopher Hillyar, University of Oxford, United Kingdom Edited by: Ming Yi, Zhejiang University, China These authors have contributed equally to this work and share first authorship Reviewed by: Tianye Li, Zhejiang University School of Medicine, China |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2024.1357601 |
PMID | 38348039 |
PQID | 2926077671 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_1db7a42248ff453b984925cc8d379180 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10859527 proquest_miscellaneous_2926077671 pubmed_primary_38348039 crossref_primary_10_3389_fimmu_2024_1357601 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-00-00 |
PublicationDateYYYYMMDD | 2024-01-01 |
PublicationDate_xml | – year: 2024 text: 2024-00-00 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2024 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Naumann (B28) 2019; 37 Koh (B8) 2015; 13 Rodrigues (B39) 2023; 14 Mezache (B14) 2015; 28 Sakaguchi (B34) 2020; 38 Li (B2) 2016; 27 Kim (B4) 2012; 84 Demaria (B40) 2021; 9 Sharabi (B38) 2015; 3 Tewari (B11) 2017; 390 Bhatla (B6) 2021 Golden (B36) 2014; 3 Curley (B18) 2020; 33 Dibbern (B15) 2020; 44 Tewari (B9) 2014; 370 Chung (B19) 2019; 37 Massague (B24) 2008; 134 Spitzer (B35) 2017; 168 Sung (B1) 2021; 71 Rahim (B5) 2023; 186 Leath (B7) 2013; 129 Chinn (B17) 2019; 74 Gao (B23) 2023; 24 Sanmamed (B13) 2018; 175 Filatenkov (B37) 2015; 21 Reticker-Flynn (B33) 2022; 185 Liu (B12) 2017; 10 Frenel (B27) 2017; 35 Yi (B25) 2021; 14 Oaknin (B26) 2022; 40 du Bois (B31) 2021; 6 Penson (B10) 2015; 16 Nathanson (B32) 2015; 38 Giuliano (B30) 2017; 318 Xia (B20) 2023; 33 Enwere (B16) 2017; 30 Da Silva (B21) 2020; 26 Cibula (B3) 2018; 127 Mayadev (B22) 2020; 6 Faries (B29) 2017; 376 |
References_xml | – volume: 318 year: 2017 ident: B30 article-title: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.11470 – volume: 13 start-page: 395 year: 2015 ident: B8 article-title: Cervical cancer, version 2.2015 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2015.0055 – volume: 74 year: 2019 ident: B17 article-title: PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy publication-title: Histopathology doi: 10.1111/his.13723 – volume: 3 year: 2014 ident: B36 article-title: Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death publication-title: Oncoimmunology doi: 10.4161/onci.28518 – volume: 9 year: 2021 ident: B40 article-title: Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-002038 – volume: 370 year: 2014 ident: B9 article-title: Improved survival with bevacizumab in advanced cervical cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1309748 – volume: 28 year: 2015 ident: B14 article-title: Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers publication-title: Mod Pathol doi: 10.1038/modpathol.2015.108 – volume: 127 year: 2018 ident: B3 article-title: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer publication-title: Radiother Oncol doi: 10.1016/j.radonc.2018.03.003 – volume: 186 start-page: 1127 year: 2023 ident: B5 article-title: Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes publication-title: Cell doi: 10.1016/j.cell.2023.02.021 – volume: 129 year: 2013 ident: B7 article-title: 3rd, Straughn JM, Jr.: Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2012.12.035 – volume: 44 year: 2020 ident: B15 article-title: Loss of MHC class I expression in HPV-associated cervical and vulvar neoplasia: A potential mechanism of resistance to checkpoint inhibition publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000001506 – volume: 390 year: 2017 ident: B11 article-title: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) publication-title: Lancet doi: 10.1016/S0140-6736(17)31607-0 – volume: 84 year: 2012 ident: B4 article-title: Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2012.01.070 – volume: 175 year: 2018 ident: B13 article-title: A paradigm shift in cancer immunotherapy: from enhancement to normalization publication-title: Cell doi: 10.1016/j.cell.2018.09.035 – volume: 33 year: 2023 ident: B20 article-title: Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study publication-title: Int J Gynecol Cancer doi: 10.1136/ijgc-2023-004705 – volume: 38 year: 2020 ident: B34 article-title: Regulatory T cells and human disease publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-042718-041717 – volume: 10 start-page: 174 year: 2017 ident: B12 article-title: Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0541-9 – volume: 37 year: 2019 ident: B19 article-title: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study publication-title: J Clin Oncol doi: 10.1200/JCO.18.01265 – volume: 168 start-page: 487 year: 2017 ident: B35 article-title: Systemic immunity is required for effective cancer immunotherapy publication-title: Cell doi: 10.1016/j.cell.2016.12.022 – volume: 3 year: 2015 ident: B38 article-title: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0196 – volume: 30 year: 2017 ident: B16 article-title: Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer publication-title: Mod Pathol doi: 10.1038/modpathol.2016.221 – volume: 33 year: 2020 ident: B18 article-title: Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia publication-title: Mod Pathol doi: 10.1038/s41379-019-0433-3 – volume: 71 year: 2021 ident: B1 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 35 year: 2017 ident: B27 article-title: Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase ib KEYNOTE-028 trial publication-title: J Clin Oncol doi: 10.1200/JCO.2017.74.5471 – volume: 21 year: 2015 ident: B37 article-title: Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2824 – volume: 376 year: 2017 ident: B29 article-title: Completion dissection or observation for sentinel-node metastasis in melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1613210 – volume: 16 year: 2015 ident: B10 article-title: Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70004-5 – volume: 26 year: 2020 ident: B21 article-title: Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929) publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-0776 – volume: 40 year: 2022 ident: B26 article-title: Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2022.40.16_suppl.5528 – volume: 6 year: 2020 ident: B22 article-title: Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.3857 – volume: 6 year: 2021 ident: B31 article-title: Tumor-draining lymph nodes: At the crossroads of metastasis and immunity publication-title: Sci Immunol doi: 10.1126/sciimmunol.abg3551 – volume: 27 year: 2016 ident: B2 article-title: Advances in diagnosis and treatment of metastatic cervical cancer publication-title: J Gynecol Oncol doi: 10.3802/jgo.2016.27.e43 – volume: 14 start-page: 27 year: 2021 ident: B25 article-title: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-beta and PD-L1 publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01045-x – volume: 185 start-page: 1924 year: 2022 ident: B33 article-title: Lymph node colonization induces tumor-immune tolerance to promote distant metastasis publication-title: Cell doi: 10.1016/j.cell.2022.04.019 – volume: 14 start-page: 3698 year: 2023 ident: B39 article-title: Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial publication-title: Nat Commun doi: 10.1038/s41467-023-39383-8 – start-page: 28 year: 2021 ident: B6 article-title: Cancer of the cervix uteri: 2021 update publication-title: Int J Gynaecol Obstet doi: 10.1002/ijgo.13865 – volume: 38 year: 2015 ident: B32 article-title: Sentinel lymph node metastases in cancer: causes, detection and their role in disease progression publication-title: Semin Cell Dev Biol doi: 10.1016/j.semcdb.2014.10.002 – volume: 24 year: 2023 ident: B23 article-title: Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(23)00411-4 – volume: 134 year: 2008 ident: B24 article-title: TGFbeta in cancer publication-title: Cell doi: 10.1016/j.cell.2008.07.001 – volume: 37 year: 2019 ident: B28 article-title: Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II checkMate 358 trial publication-title: J Clin Oncol doi: 10.1200/JCO.19.00739 |
SSID | ssj0000493335 |
Score | 2.3578608 |
Snippet | Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a... BackgroundDespite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1357601 |
SubjectTerms | case report cervical cancer Immunology immunotherapy lymph node metastasis radiotherapy |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1dS-QwFA0iLPiy6Lofo-sSYd-WYtuk-fBlUVkVQZ8UZF9CPtkRpx1mOg_z771JqszIgi8-FdrQpuc03HPT5FyEfgovDITFsmgkc0V0wCpMzUNBrCa147xkaR_39Q27vKNX9839SqmvuCYs2wNn4I4qZ7imEGhECLQhRopop2etcITLSqRsHWLeSjL1kHUvIaTJu2QgC5NHYTyZLCAfrGks9RBXgqxFomTY_z-V-Xqx5Er0Od9GHwfZiE9yd3fQhm8_oQ-5kORyF_09g2CE8_z_Mb4Aynv8uASicNs5jye-16AC535-jDUGIY27aWy6gPG8xCBbsY3kz_BMu3EXX6EdNmYtf39Gd-d_bs8ui6FqQmFpXfYgl40HmChnMDwNdQTCIOFVzUwQ2umK6ZJSaSyrfLBBh0pDkxKOtWuC44Z8QZtt1_pvCCcaoz9PcBSEnZcW7sAto0ybIJkfoV_PCKppNsdQkFREvFXCW0W81YD3CJ1GkF9aRmPrdALoVgPd6i26R-jwmSIFAyH-3dCt7xZzVUtIzaI3ETzoa6bs5VGQhlNREjlCYo3Mtb6sX2nH_5LZdpUc4Gq-9x6930dbEZE8hfMdbfazhT8AUdObH-n7fQJB4_WY priority: 102 providerName: Directory of Open Access Journals |
Title | Case report: Giant lymph node metastases: a new opportunity for cancer radioimmunotherapy? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38348039 https://www.proquest.com/docview/2926077671 https://pubmed.ncbi.nlm.nih.gov/PMC10859527 https://doaj.org/article/1db7a42248ff453b984925cc8d379180 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA_nieCL-O36cUTwTaptkybpgRx6eHcI55MLiy8hn7py257dLtj_3pm0e7hyvvnSQps2yUyG-U0-fkPIKxWUBbeYZ1UtfIYMWJktZcyYM6z0UuYineM-_yzO5vzTolrskW26o0mA62tDO8wnNe8u3vz6ORyBwb_DiBP87du4XK02EOqVHLM44CaPG-QmeCaJGQ3OJ7j_Y0TDjLFqPDvzj093_FOi8b8Oe_69hfIPn3Ryl9yZwCR9P2r_HtkLzX1ya0wvOTwgX4_BRdFxVeCQnsJA6OnFAOqjTesDXYXeADZch_UhNRTgNW0vsegGrHygAGapwyHR0c74ZYtdaKbjWsPRQzI_-fjl-Cybcilkjpd5DyDaBmZrLgUYreWegXNksiiFjcp4UwiTc15bJ4oQXTSxMFAkh3vpq-ilZY_IftM24QmhSbnI2hM9B7gXagd_kE5wYWysRZiR11sJ6suRMkNDqIHy1kneGuWtJ3nPyAcU8lVJpLtOD9rum56sRxfeSsMBbagYeQX9UMip6JzyTNaFymfk5VZFGswD1zxME9rNWpc1BGzIWAQVPR5VdlUVBOdc5ayeEbWjzJ227L5plt8TBXeReOFK-fR_tP4ZuY0SGSd2npP9vtuEFwB1enuQpgjgerooDtJY_g1a2QCZ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Case+report%3A+Giant+lymph+node+metastases%3A+a+new+opportunity+for+cancer+radioimmunotherapy%3F&rft.jtitle=Frontiers+in+immunology&rft.au=Yuan+Bian&rft.au=Zhenhua+Zhang&rft.au=Xiangyu+Deng&rft.au=Qinglian+Wen&rft.date=2024&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=15&rft_id=info:doi/10.3389%2Ffimmu.2024.1357601&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1db7a42248ff453b984925cc8d379180 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |